Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - benzatropine mesilate, quantity: 2 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; magnesium stearate - indicated for the treatment of all forms of parkinsonism. the treatment of extrapyramidal reactions (except tardive dyskinesia [see contraindications and precautions]) due to neuroleptic drugs.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - probenecid, quantity: 500 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; stearic acid; magnesium stearate; maize starch; microcrystalline cellulose; povidone; macrogol 8000; hypromellose; macrogol 400; titanium dioxide; sunset yellow fcf; polysorbate 80; quinoline yellow - indications as at 25 may 2000 : gout - probenecid is a uricosuric agent for the treatment of hyperuricaemia in all stages of gout and gouty arthritis except an acute attack. asymptomatic hyperuricaemia seems to occur in a significant percentage of relatives of gouty patients. probenecid may be given prophylactically to these people to forestall gouty attacks and urate deposition in tissues. by virtue of its effective uricosuric activity, probenecid may be used to control the hyperuricaemia induced or aggravated by many diuretics employed for the treatment of oedema and hypertension (e.g. thiazides and smiliar diuretics). b-lactam antibiotic therapy - probenecid is indicated for the elevation and prolongation of plasma levels by whatever route the antibiotic is given. a two-to-fourfold increase in plasma levels has been demonstrated for benzylpenicillin, phenoxymethylpenicillin, the synthetic penicillins, ampicillin, methicillin, oxacillin, cloxacillin, nafcillin, carbenicillin, and for the cephamycin, mefoxin (cefoxitin sodium, msd), and the cephalosporins, cephalothin, cephalexin and cephaloglycin. because of its mechanisim of action, probenecid is not recommended in conjunction with a b-lactam antibiotic in the presence of known renal impairment. concurrent treatment with cidofovir for cmv retinitis in hiv patients. probenecid is recommended to be administered concomitantly with cidofovir, as the combination reduces the potential for nephrotoxicity associated with cidofovir.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - naloxone hydrochloride dihydrate, quantity: 440 microgram (equivalent: naloxone hydrochloride?, qty 400 microgram) - injection - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - narcan is indicated for the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic antagonist analgesics: nalbuphine, pentazocine and butorphanol. narcan is also indicated for the diagnosis of suspected acute opioid overdosage.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - droperidol, quantity: 2.5 mg/ml - injection, solution - excipient ingredients: tartaric acid; mannitol; water for injections - in anaesthesia - drolepton is indicated to produce tranquillisation and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures; for premedication, induction, and as an adjunct in the maintenance of general and regional anaesthesia; in neuroleptanalgesia in which droleptan is given concurrently with a narcotic analgesic, to aid in producing tranquillity and decreasing anxiety and pain. in psychiatry - the management of severe agitation, hyperactivity, or agressiveness in psychotic disorders, including schizophrenic reaction and the manic type of manic depressive illness, or in disturbed states, such as some types of acute brain syndrome and in nonpsychotic acute excitation states.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - esmolol hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium acetate trihydrate; glacial acetic acid - supraventricular tachycardia - for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol is also indicated in non-compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. esmolol is not intended for use in chronic settings where transfer to another agent is anticipated, or for treatment periods greater than 24 hours duration.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - metaraminol tartrate, quantity: 18.96 mg (equivalent: metaraminol, qty 10 mg) - injection - excipient ingredients: sodium metabisulfite; sodium chloride; water for injections; sodium hydroxide; tartaric acid - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma.,it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - metaraminol tartrate, quantity: 18.96 mg (equivalent: metaraminol, qty 10 mg) - injection - excipient ingredients: water for injections; sodium metabisulfite; sodium chloride; sodium hydroxide; tartaric acid - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma.,it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - fluorescein sodium, quantity: 250 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - indications as at 01 january 1991 : diagnostic - intravenous injection of sodium fluorescein dye followed by multiframe photography (angiography) or ophthalmoscopic evaluation (angioscopy). used in evaluation of wide range of retinal and choroidal diseases. less commonly used to evaluate abnormalities of the optic nerve and iris. may be used in diagnosis and management of macular and vascular (including diabetes) diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - fluorescein sodium, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - indications as at 01 january 1991 : diagnostic - intravenous injection of sodium fluorescein dye followed by multiframe photography (angiography) or ophthalmoscopic evaluation (angioscopy). used in evaluation of wide range of retinal and choroidal diseases. less commonly used to evaluate abnormalities of the optic nerve and iris. may be used in diagnosis and management of macular and vascular (including diabetes) diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - quinine dihydrochloride, quantity: 60 mg/ml - injection, solution - excipient ingredients: water for injections - indications as at 1 january 1991 : acute treatment of malaria. it may also be used in the treatment of babesiosis in conjunction with clindamycin.